Mode
Text Size
Log in / Sign up

PEFR-guided therapy shows no difference in symptom control compared to symptom-guided therapy in acute asthmaTrial shows PEFR values do not change asthma treatment outcomes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that PEFR-guided therapy did not improve symptom control or resource use compared to symptom-guided care.

This pilot randomized controlled trial enrolled 210 patients aged 16 to 55 years presenting with acute asthma in an Emergency Department setting. The study compared PEFR-guided therapy, where clinicians received peak expiratory flow values and guideline recommendations, against symptom-guided therapy, where clinicians were blinded to PEFR values.

Regarding the primary outcome, 72% of patients in the PEFR-guided group achieved none or mild asthma symptoms by 150 minutes compared to 72% in the non-PEFR-guided group (95% CI, -11% to 13%). Secondary outcomes also showed no significant differences: hospitalization occurred in 17% of the PEFR group versus 12% of the non-PEFR group (95% CI, -5% to 14%), and no difference was reported for nebulized medication use.

Safety data, including adverse events and tolerability, were not reported. The study is limited by its status as a pilot study with a small sample size for definitive practice changes. These findings suggest that PEFR-guided care did not improve symptom control or reduce resource utilization compared to symptom-guided care in the emergency department setting.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in acute asthma management protocols by evaluating the utility of objective measurements like peak expiratory flow. While previous coverage noted that bidirectional associations exist between obstructive lung diseases and inflammatory bowel disease, this study specifically focuses on the immediate clinical management of acute asthma symptoms in an emergency setting.

Researchers conducted a pilot study to see if using Peak Expiratory Flow Rate (PEFR) values helped doctors treat patients with acute asthma in the emergency department. The study included 210 patients between the ages of 16 and 55 who did not have chronic obstructive pulmonary disease.

In one group, clinicians received PEFR values along with guideline-based recommendations. In the other group, clinicians were not shown these values and instead guided treatment based on symptoms alone. The results showed that both groups had similar success rates. Specifically, 72% of patients in both groups had none or mild asthma symptoms within 150 minutes.

There was also no significant difference in hospitalizations or the use of nebulized medications between the two groups. Because this was a small pilot study, the results are not enough to change standard medical practices yet. These findings suggest that adding PEFR values may not offer extra benefits for managing acute asthma in emergency settings.

What this means for you:
This pilot study found no significant difference in outcomes when using peak flow measurements for acute asthma care.

Common questions

Does using peak flow readings help treat acute asthma faster?

This pilot study of 210 patients found no significant difference in how quickly symptoms were controlled when doctors used peak flow values compared to when they only looked at symptoms. In both groups, 72% of patients had mild or no symptoms within 150 minutes.

Does peak flow data reduce hospital stays for asthma?

The study found that using peak flow values did not lead to a lower rate of hospitalization. The results showed 17% of the peak flow group and 12% of the symptom-guided group were hospitalized, which was not a statistically significant difference.

Is this study enough to change how doctors treat asthma?

No, because this was a small pilot study with only 210 participants. The researchers noted that larger multicenter studies are needed before these findings can be used to change standard medical practices for asthma management.

Study Details

Study typeRct
Sample sizen = 210
EvidenceLevel 2
Follow-up660.0 mo
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Peak expiratory flow rate (PEFR) is used to assess asthma severity, and guidelines recommend serial PEFR measurements to guide management. However, the evidence behind this practice is limited. OBJECTIVES: To compare outcomes between PEFR-guided and non-PEFR-guided emergency department (ED) care for acute asthma exacerbations. METHODS: This randomized, unblinded, two-arm study compared PEFR-guided therapy with symptom-guided therapy in ED patients aged 16 to 55 years presenting with acute asthma without chronic obstructive pulmonary disease (COPD). Patients were enrolled within 15 min of their first nebulizer treatment. PEFR was measured at baseline and every 30 min until symptom resolution, discharge, or admission. Clinicians in the PEFR-guided group received PEFR values with guideline-based recommendations, while clinicians in the non-PEFR-guided group were blinded to PEFR values. The primary outcome was the proportion of patients with none or mild asthma symptoms by 150 min after enrollment. The secondary outcome was hospitalization. RESULTS: A total of 210 patients were enrolled (101 PEFR-guided; 109 non-PEFR-guided). Symptom control by 150 min occurred in 73 (72%) vs. 78 (72%) patients (95% CI, -11% to 13%). Hospitalization was similar: 17 (17%) in the PEFR group vs. 13 (12%) in the non-PEFR group (95% CI, -5% to 14%). Subgroup hospitalization results by percent-predicted PEFR were comparable. There was no difference in nebulized medication use. CONCLUSION: In this randomized trial, PEFR-guided care did not improve symptom control, reduce resource utilization, or affect disposition compared with symptom-guided care. These findings suggest limited benefit of PEFR use in ED asthma management. Larger, multicenter studies are needed before informing practice changes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.